A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Renal Cell
BEZ235 twice daily resulted in significant toxicity without objective responses; further development of this compound will not be pursued in this disease.
PubMed Central ID
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency